Relmada Therapeutics Stock (NASDAQ:RLMD)
Previous Close
$3.02
52W Range
$1.88 - $7.22
50D Avg
$3.37
200D Avg
$3.82
Market Cap
$89.92M
Avg Vol (3M)
$180.95K
Beta
0.41
Div Yield
-
RLMD Company Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PRDS | Pardes Biosciences, Inc. |
| NLTX | Neurogene Inc. |
| DYN | Dyne Therapeutics, Inc. |
| BCYC | Bicycle Therapeutics plc |
| CYTK | Cytokinetics, Incorporated |
| CSBR | Champions Oncology, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| RAPT | RAPT Therapeutics, Inc. |
| ENOB | Renovaro Biosciences Inc. |
| FUSN | Fusion Pharmaceuticals Inc. |
| MGTA | Dianthus Therapeutics, Inc. |